Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onfi Approval Shows Benefits Of Lundbeck's Ovation Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Clobazam is approved as an add-on to therapy for a particularly severe orphan seizure disorder known as Lennox-Gastaut syndrome.
Advertisement

Related Content

Lundbeck Onfi Gets Dermatological Warning, Bigger Marketing Challenge
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck Invests £10M In CNS-Focused Proximagen
MDD Market Snapshot: Depressing Future For Antidepressants
Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry

Topics

Advertisement
UsernamePublicRestriction

Register

PS072928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel